Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by M101on Oct 06, 2022 7:25pm
136 Views
Post# 35011022

RE:Herpes is the cause

RE:Herpes is the causeThat's a stretch, but then so were all of what Elliot liked to call 1st generation AD drugs.

What is the logic that evolution would produce a chemical that keeps great grandparents in already long lived species alive longer? Yet this was the assumption behind discovering and modifying natural compounds that were found serendipitously to offer some marginal statistical benefit to some AD populations.   
I'd rather compare 1st gen AD drugs to Twain's definition of a gold mine: a hole in the ground with a liar standing at the top.  
Again, should not be difficult for a competent CEO to differentiate Promis' designer drug and fold-specific epitope from what investors are used to from big pharma and their high priced echo chambers.
And that's why finding investors has been so tough under the clown regime, jmho. 
<< Previous
Bullboard Posts
Next >>